PharmaVoice 100s: Clinical trial gurus

Industry leaders adopting cutting-edge technologies and strategies to change the paradigm of clinical research.

By Meagan Parrish • Oct. 19, 2023

For women’s health, Organon changed the financial language

Organon is partnering with governments, banks, NGOs and investors on programs to improve women’s health through results-based financing.

By Alexandra Pecci • Oct. 18, 2023

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

From the rainforest to Wall Street — Jaguar Health’s big play for revitalization

A pharma with a massive collection of rainforest-derived plants needs a regulatory win to overcome last year’s financial decline.

By Kelly Bilodeau • Oct. 17, 2023

The FDA might yank cold medicines from shelves — and that could be just the beginning

Phenylephrine’s future is up in the air with an FDA committee saying it’s not effective and a class action lawsuit alleging false advertising. What comes next could have big repercussions.

By Alexandra Pecci • Oct. 17, 2023

The top biopharma conferences in 2024

A few key meetings remain this year, like ESMO and ASH, while next year’s events are already being planned. Here’s a list of conferences to keep in mind.

By Ned Pagliarulo • Oct. 16, 2023

Has the science of anti-aging caught up with the dream of a longer life?

Billionaire investors and a new crop of longevity biotechs are betting big money on a lifespan-altering tipping point.

By Kelly Bilodeau • Oct. 16, 2023

PharmaVoice 100s: Rare disease warriors

Biopharma leaders pounding away at rare diseases so patients with few other options can have healthier lives.

By Michael Gibney • Oct. 16, 2023

Branded: The trademarks pharma leaders look up to

What do brands like Patagonia, Nike and Lego have to do with pharma? Here are some of the brands industry leaders relate to most — and how they inspire work in the life sciences.

By PharmaVoice Staff • Oct. 13, 2023

PharmaVoice 100s: Patient heroes

Leaders innovating new ways to incorporate patient voices in drug development and decrease barriers to access. 

By Karissa Waddick • Oct. 13, 2023

Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future

Yvonne Greenstreet, CEO of RNAi specialist Alnylam, addressed the surprise move by regulators and the company’s new future plans.

By Michael Gibney • Oct. 12, 2023

A decade later, biotech’s CRISPR revolution is still going strong

Once the specialty of a few select drugmakers, CRISPR gene editing is now an essential technology for a growing group of biotechs, many led by former students of the field's pioneering scientists.

By Gwendolyn Wu , Shaun Lucas , Julia Himmel • Oct. 12, 2023

5 minutes with — IDEA Pharma’s Mike Rea

The CEO on the secrets of innovative pharma companies, his record collection and what he’d always rather be doing.

By Meagan Parrish • Oct. 11, 2023

Google bets on AI in the life sciences as ‘technology for a purpose’

A life sciences exec at Google Cloud talks about the future and fears for using AI in pharma.

By Alexandra Pecci • Oct. 10, 2023

PharmaVoice 100s: Tech wizards

The leaders paving the way to pharma’s future with state-of-the-art digital solutions.

By Karissa Waddick • Oct. 9, 2023

Key upcoming events for pharma execs

Trade shows and events focused on the industry’s hot-button topics, technologies and trends.

By Meagan Parrish • Oct. 6, 2023

3 marketing tips for biotechs emerging from stealth

In a crowded biotech market, here’s how your company can stand out to investors.

By Karissa Waddick • Oct. 6, 2023

FDA’s ‘ivory tower thinking’ ignores promising biomarkers, says a rare disease CEO

The FDA wouldn’t review a drug that was 90% effective. In rare diseases, this is too common, said Ultragenyx CEO Dr. Emil Kakkis and a leading rare disease researcher.

By Michael Gibney • Oct. 5, 2023

Drugmakers face uphill battle in Medicare negotiation suits

Judges have found fault with drug manufacturers’ First and Fifth Amendment arguments against the IRA’s drug pricing measures.

By Karissa Waddick • Oct. 4, 2023

5 FDA decisions to watch in the fourth quarter

The regulator is considering approval of what would be the first CRISPR medicine, as well as important clearances for Alnylam, Bristol Myers, Amgen and Pfizer.

By Ned Pagliarulo , Jonathan Gardner • Oct. 2, 2023

PharmaVoice 100s: Cancer care visionaries

Leaders shaping the future of oncology and cancer care through grit and determination in the face of one of healthcare’s greatest challenges.

By Michael Gibney • Oct. 2, 2023

3 recent FDA adcomm rejections — and why they matter

Decisions that could spell doom for drugs in development and already on the shelves.

By Meagan Parrish • Sept. 29, 2023

The PharmaVoice 100: Trailblazers

Leaders who are going where no biopharma executive has gone before and changing the industry along the way.

By Michael Gibney • Sept. 29, 2023

How pharma marketers can reclaim the drug pricing narrative

As Medicare negotiations heat up, it’s more important than ever for pharma companies to communicate their value. Here’s how.

By Karissa Waddick • Sept. 28, 2023

Pfizer CEO Albert Bourla led Big Pharma bonus payouts over 5 years — but he’s no Elon Musk

A recent report showed how pharma’s bonuses pale in comparison to other industries, but several execs still rake in hefty packages.

By Michael Gibney • Sept. 28, 2023

Inside Bavarian Nordic’s late-stage stumbles — and drive to become a vaccine giant

Despite recent phase 3 setbacks in RSV and COVID-19, CEO Paul Chaplin sees a promising path forward in the travel vaccine market for the Danish biotech.

By Karissa Waddick • Sept. 27, 2023